{
  "nct_id": "NCT37002837",
  "indication": "Multiple Sclerosis",
  "phase": "Phase 1",
  "sample_size": 57,
  "duration_weeks": 18,
  "dropout_rate": 0.09,
  "blinding": "double-blind",
  "control_arm": "active comparator",
  "primary_endpoints": [
    "EDSS score change"
  ],
  "secondary_endpoints": [
    "New T2 lesions",
    "Relapse rate reduction"
  ],
  "outcome_summary": "Statistically significant clinical benefit observed",
  "success": 1,
  "start_date": "2021-08-22",
  "completion_date": "2021-12-26"
}